| pubmed-article:8487050 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8487050 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8487050 | lifeskim:mentions | umls-concept:C1514695 | lld:lifeskim |
| pubmed-article:8487050 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:8487050 | lifeskim:mentions | umls-concept:C0555198 | lld:lifeskim |
| pubmed-article:8487050 | lifeskim:mentions | umls-concept:C0007257 | lld:lifeskim |
| pubmed-article:8487050 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:8487050 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:8487050 | lifeskim:mentions | umls-concept:C1831915 | lld:lifeskim |
| pubmed-article:8487050 | lifeskim:mentions | umls-concept:C0332293 | lld:lifeskim |
| pubmed-article:8487050 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8487050 | pubmed:dateCreated | 1993-6-4 | lld:pubmed |
| pubmed-article:8487050 | pubmed:abstractText | The purpose is twofold: (1) to identify the malignant glioma patients treated in a trial of hyperfractionated radiotherapy (RT) and carmustine (BCNU) who may have been eligible for a stereotactic radiosurgery (SRS) boost; and (2) to compare survival of such patients with that of those considered SRS-ineligible. | lld:pubmed |
| pubmed-article:8487050 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8487050 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8487050 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8487050 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8487050 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8487050 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8487050 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8487050 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8487050 | pubmed:month | May | lld:pubmed |
| pubmed-article:8487050 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8487050 | pubmed:author | pubmed-author:MurrayKK | lld:pubmed |
| pubmed-article:8487050 | pubmed:author | pubmed-author:PhillipsT LTL | lld:pubmed |
| pubmed-article:8487050 | pubmed:author | pubmed-author:SchwadeJ GJG | lld:pubmed |
| pubmed-article:8487050 | pubmed:author | pubmed-author:NelsonJ SJS | lld:pubmed |
| pubmed-article:8487050 | pubmed:author | pubmed-author:YakarDD | lld:pubmed |
| pubmed-article:8487050 | pubmed:author | pubmed-author:ScottC BCB | lld:pubmed |
| pubmed-article:8487050 | pubmed:author | pubmed-author:MartinL ALA | lld:pubmed |
| pubmed-article:8487050 | pubmed:author | pubmed-author:CurranW JWJJr | lld:pubmed |
| pubmed-article:8487050 | pubmed:author | pubmed-author:WeinsteinA... | lld:pubmed |
| pubmed-article:8487050 | pubmed:author | pubmed-author:FischbachA... | lld:pubmed |
| pubmed-article:8487050 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8487050 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:8487050 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8487050 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8487050 | pubmed:pagination | 857-62 | lld:pubmed |
| pubmed-article:8487050 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8487050 | pubmed:meshHeading | pubmed-meshheading:8487050-... | lld:pubmed |
| pubmed-article:8487050 | pubmed:meshHeading | pubmed-meshheading:8487050-... | lld:pubmed |
| pubmed-article:8487050 | pubmed:meshHeading | pubmed-meshheading:8487050-... | lld:pubmed |
| pubmed-article:8487050 | pubmed:meshHeading | pubmed-meshheading:8487050-... | lld:pubmed |
| pubmed-article:8487050 | pubmed:meshHeading | pubmed-meshheading:8487050-... | lld:pubmed |
| pubmed-article:8487050 | pubmed:meshHeading | pubmed-meshheading:8487050-... | lld:pubmed |
| pubmed-article:8487050 | pubmed:meshHeading | pubmed-meshheading:8487050-... | lld:pubmed |
| pubmed-article:8487050 | pubmed:meshHeading | pubmed-meshheading:8487050-... | lld:pubmed |
| pubmed-article:8487050 | pubmed:meshHeading | pubmed-meshheading:8487050-... | lld:pubmed |
| pubmed-article:8487050 | pubmed:meshHeading | pubmed-meshheading:8487050-... | lld:pubmed |
| pubmed-article:8487050 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8487050 | pubmed:articleTitle | Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. | lld:pubmed |
| pubmed-article:8487050 | pubmed:affiliation | Fox Chase Cancer Center, Philadelphia, PA 19111. | lld:pubmed |
| pubmed-article:8487050 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8487050 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8487050 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8487050 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8487050 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:8487050 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:8487050 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8487050 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8487050 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8487050 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8487050 | lld:pubmed |
